银屑病患儿系统治疗与严重感染风险的倾向评分匹配研究
该研究利用保险理赔数据,纳入57323例18岁以下银屑病患儿,比较启动生物制剂、系统性非生物制剂与光疗者6个月内严重感染的发生频率,并在1:1倾向评分匹配前后估计相对风险。结果显示各治疗组间感染风险无显著差异,而银屑病患儿本身的感染背景风险约为无银屑病儿童的近两倍。
要点
- 银屑病患儿6个月感染背景风险为1/1000,约为无银屑病儿童的1.84倍
- 生物制剂与非生物制剂、系统治疗与光疗之间感染风险均无显著差异
- 临床决策时需关注银屑病本身带来的感染风险,而非仅关注药物选择
核心结论
- 生物制剂与系统性非生物制剂之间、系统治疗与光疗之间未见有意义的感染风险差异。
- 独立于治疗方式,银屑病患儿感染风险高于无银屑病儿童。
研究设计与样本
- 基于保险理赔数据的倾向评分匹配人群研究,纳入57323例18岁以下银屑病患儿。
- 比较启动生物制剂、系统性非生物制剂与光疗者6个月内严重感染频率,匹配前后估计相对风险。
主要发现
- 6个月感染风险:生物制剂启动者722例中为4.2/1000患者年,系统性非生物制剂988例中为5.1,光疗2657例中为1.1。
- 生物制剂vs非生物制剂相对风险0.67(95%CI 0.11-3.98),生物制剂vs光疗1.50(0.25-8.95),非生物制剂vs光疗5.00(0.59-42.71)。
- 银屑病患儿感染背景风险为1/1000,约为无银屑病儿童的1.84倍(95%CI 1.15-1.97)。
关键数值与推荐
- 生物制剂vs非生物制剂感染相对风险0.67(95%CI 0.11-3.98)。
- 生物制剂vs光疗感染相对风险1.50(95%CI 0.25-8.95)。
- 非生物制剂vs光疗感染相对风险5.00(95%CI 0.59-42.71)。
- 银屑病vs无银屑病儿童感染相对风险1.84(95%CI 1.15-1.97)。
临床怎么用
- 儿童银屑病系统治疗选择时,感染风险在生物制剂与非生物制剂间无显著差异,可结合疗效与安全性综合决策。
- 应认识到银屑病患儿本身感染风险较高,治疗前后需关注感染监测。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis is increasingly treated with systemic medications, yet their safety is not well characterized in children. OBJECTIVE: We sought to estimate the 6-month risk of serious infections in children with psoriasis treated with biologics, systemic nonbiologics, and phototherapy. METHODS: Using insurance claims data, we identified children aged <18 years with psoriasis and compared the frequency of serious infections in those initiating biologics, systemic nonbiologics, and phototherapy. Relative risks were estimated before and after 1:1 propensity score matching. RESULTS: Among 57,323 children with psoriasis, the 6-month risk of infection was 4.2 per 1000 patient-years in 722 biologic initiators, 5.1 in 988 systemic nonbiologic initiators, and 1.1 in 2657 phototherapy initiators. The relative risk (95% confidence interval) of infection in biologics vs nonbiologics was 0.67 (0.11-3.98), in biologics vs phototherapy was 1.50 (0.25-8.95), and in nonbiologics vs phototherapy was 5.00 (0.59-42.71). The background risk of infection in children with psoriasis was 1 per 1000, almost double the risk compared with children without psoriasis (relative risk, 1.84; 95% confidence interval, 1.15-1.97). CONCLUSIONS: We found no meaningful difference in infection risk between biologics vs nonbiologics and no robust difference between systemic users vs phototherapy. Independent of treatment, children with psoriasis had a higher risk of infection than those without psoriasis.
引用
- Schneeweiss MC, Huang JT, Wyss R, et al. Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study. J Am Acad Dermatol. 2020. PMID: 32142748. doi:10.1016/j.jaad.2020.02.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。